|
Canadian Pharmacy |
|
|
|
 |
|
Clinical Pharmacology
Absorption
Nexium delayed-release capsule contains an enteric-coated pellet which is
a formulation of esomeprazole magnesium. After oral administration peak
plasma levels (Cmax) occur at approximately 1.5 hours (Tmax). When the doses
is increased the Cmax increase in the proportional manner, and there is
also three-fold increase in the area under the plasma concentration-time
curve from 20mg to 40 mg. The repetition of a once-daily dosing is with
40 mg, after taking a single dose of 40 mg, the systemic bioavailability
is around 90% compared to 64%. The mean exposure (AUC) to esomeprazole increases
from 4.32 µmol*hr/L on day 1 to 11.2 µmol*hr/L on day 5 after
40 mg once daily dosing.
The AUC after administration of a single 40 mg dose of esomeprazole is decreased
by 43 to 53% after food intake compared to fasting conditions. It is advisable
if you take esomeprazole at least one hour before meals. The pharmacokinetic
profile of Esomeprazole was determined in 40 patients with symptomatic gastroesophageal
reflux disease following repeated once daily administration of 20 mg and
40 mg capsules of Nexium over a period of five days.
|
|
|
Nexium Articles |
|
|
|
|
|
|
CUSTOMER SERVICE |
 |
 |
